Zacks: Analysts Expect Idera Pharmaceuticals Inc (IDRA) Will Announce Quarterly Sales of $130,000.00

Equities analysts predict that Idera Pharmaceuticals Inc (NASDAQ:IDRA) will post sales of $130,000.00 for the current quarter, according to Zacks. Two analysts have issued estimates for Idera Pharmaceuticals’ earnings, with the highest sales estimate coming in at $150,000.00 and the lowest estimate coming in at $100,000.00. Idera Pharmaceuticals posted sales of $260,000.00 during the same quarter last year, which would indicate a negative year over year growth rate of 50%. The business is scheduled to report its next quarterly earnings results on Wednesday, May 8th.

On average, analysts expect that Idera Pharmaceuticals will report full year sales of $490,000.00 for the current financial year, with estimates ranging from $400,000.00 to $580,000.00. For the next fiscal year, analysts expect that the business will report sales of $6.79 million, with estimates ranging from $420,000.00 to $13.15 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Idera Pharmaceuticals.

Idera Pharmaceuticals (NASDAQ:IDRA) last issued its quarterly earnings data on Wednesday, March 6th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.06. Idera Pharmaceuticals had a negative return on equity of 75.10% and a negative net margin of 9,045.47%. The business had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.12 million.

IDRA has been the subject of a number of recent analyst reports. Wedbush set a $7.00 price objective on Idera Pharmaceuticals and gave the stock an “outperform” rating in a report on Thursday, March 7th. HC Wainwright decreased their price target on Idera Pharmaceuticals to $14.00 and set a “buy” rating for the company in a research note on Friday, March 8th. Zacks Investment Research lowered Idera Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, January 25th. Finally, ValuEngine raised Idera Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. Idera Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $16.71.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Virtu Financial LLC acquired a new stake in shares of Idera Pharmaceuticals during the 4th quarter valued at $33,000. Assenagon Asset Management S.A. acquired a new stake in shares of Idera Pharmaceuticals during the 4th quarter valued at $1,153,000. Candriam Luxembourg S.C.A. lifted its position in shares of Idera Pharmaceuticals by 48.7% during the 4th quarter. Candriam Luxembourg S.C.A. now owns 290,000 shares of the biotechnology company’s stock valued at $803,000 after acquiring an additional 95,000 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Idera Pharmaceuticals during the 3rd quarter valued at $200,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Idera Pharmaceuticals during the 3rd quarter valued at $132,000. 44.71% of the stock is owned by hedge funds and other institutional investors.

IDRA stock traded down $0.04 on Tuesday, reaching $2.39. The company’s stock had a trading volume of 158,287 shares, compared to its average volume of 254,546. Idera Pharmaceuticals has a 52 week low of $2.25 and a 52 week high of $17.12. The firm has a market capitalization of $66.01 million, a price-to-earnings ratio of -1.05 and a beta of 2.55.

Idera Pharmaceuticals Company Profile

Idera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer.

Featured Article: Outstanding Shares, Buying and Selling Stocks

Get a free copy of the Zacks research report on Idera Pharmaceuticals (IDRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Idera Pharmaceuticals (NASDAQ:IDRA)

Receive News & Ratings for Idera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.